8-K: bioAffinity Technologies Notified by Nasdaq of Failure to Meet Minimum Bid Price Requirement

bioAffinity Technologies received a notice from Nasdaq on February 7, 2025, stating that its common stock has not maintained the minimum closing bid price of $1.00 per share for the preceding 30 consecutive business days.

Summary

• bioAffinity Technologies, Inc. received a notification from Nasdaq on February 7, 2025, indicating non-compliance with the minimum bid price requirement.
• The company's common stock (BIAF) failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days, from December 23, 2024, to February 6, 2025.
• This notice does not immediately affect the listing or trading of the company's stock on The Nasdaq Capital Market.
• bioAffinity Technologies has a 180-day compliance period, until August 6, 2025, to regain compliance.
• Compliance can be achieved if the stock's closing bid price is at or above $1.00 for at least ten consecutive business days during the compliance period.
• If compliance is not achieved by August 6, 2025, the company may be eligible for additional time, provided it meets other listing requirements.
• The company intends to monitor the bid price and consider options to regain compliance.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the delisting notice, but the company has time to regain compliance. The intention to monitor and consider options is a mildly positive sign.

Positives

• The notice has no immediate effect on the listing or trading of bioAffinity Technologies' common stock.
• The company has a 180-day compliance period to regain compliance with Nasdaq listing rules.
• The company may be eligible for additional time to comply if it meets other listing requirements.

Negatives

• bioAffinity Technologies' common stock has failed to maintain the minimum bid price of $1.00 for 30 consecutive business days.
• Failure to regain compliance by August 6, 2025, could lead to delisting from The Nasdaq Capital Market.

Risks

• There is a risk of delisting from The Nasdaq Capital Market if bioAffinity Technologies fails to regain compliance with the minimum bid price requirement by August 6, 2025.
• The company's ability to regain compliance depends on market conditions and its ability to increase its stock price.
• Failure to meet other listing requirements could prevent the company from being eligible for additional time to comply.

Future Outlook

The company intends to actively monitor the bid price of its common stock and will consider available options to regain compliance with the Nasdaq listing requirements.

Industry Context

Many small-cap biotech companies face challenges in maintaining share price compliance, especially during periods of market volatility or when clinical trial results are pending. This notice highlights the importance of achieving milestones and maintaining investor confidence to support the stock price.

Comparison to Industry Standards

• Many companies in the biotech sector, particularly those in early stages of development, face similar challenges in maintaining Nasdaq compliance.
• Companies like 'Celcuity Inc' and 'Onconetix Inc' have faced similar delisting warnings in the past.
• The 180-day compliance period is standard for Nasdaq deficiency notices, providing a window for companies to improve their stock performance.

Stakeholder Impact

• Shareholders may experience concern due to the potential for delisting.
• Employees may face uncertainty regarding the company's future.
• The company's reputation and ability to attract investment could be negatively impacted.

Next Steps

• bioAffinity Technologies will actively monitor its stock price.
• The company will consider available options to regain compliance with Nasdaq listing requirements.
• The company must achieve a closing bid price of $1.00 or higher for at least ten consecutive business days before August 6, 2025.

Key Dates

Keywords

Nasdaq, minimum bid price, compliance, listing rule, bioAffinity Technologies, BIAF, delisting